|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| CURRENT ASSETS: | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Accounts receivable, net of allowance for credit losses of $6,552 and $6,317 at 2026 and 2025, respectively | ||||||||||||||
| Inventories | ||||||||||||||
| Prepaid expenses | ||||||||||||||
| Income taxes receivable | ||||||||||||||
| Other current assets | ||||||||||||||
| TOTAL CURRENT ASSETS | ||||||||||||||
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $321,722 and $320,707 at 2026 and 2025, respectively | ||||||||||||||
| RIGHT OF USE ASSETS | ||||||||||||||
| INTANGIBLES, net of accumulated amortization and impairment of $19,988 and $19,531 at 2026 and 2025, respectively | ||||||||||||||
| GOODWILL | ||||||||||||||
| DEFERRED TAX ASSETS, net | ||||||||||||||
| OTHER ASSETS | ||||||||||||||
| TOTAL ASSETS | ||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||
| Accounts payable | ||||||||||||||
| Accrued payroll and related costs | ||||||||||||||
| Taxes other than payroll and income | ||||||||||||||
| Unearned revenues | ||||||||||||||
| Operating lease liabilities | ||||||||||||||
| Income taxes payable | ||||||||||||||
| Other current liabilities | ||||||||||||||
| TOTAL CURRENT LIABILITIES | ||||||||||||||
| LONG-TERM DEBT, net | ||||||||||||||
| LONG-TERM OPERATING LEASE LIABILITIES | ||||||||||||||
| DEFERRED COMPENSATION | ||||||||||||||
| DEFERRED TAX LIABILITIES, net | ||||||||||||||
| OTHER LONG-TERM LIABILITIES | ||||||||||||||
| EQUITY: | ||||||||||||||
| Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding | ||||||||||||||
| Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 45,808,096 outstanding at 2026; 46,966,868 issued and 46,095,379 outstanding at 2025 | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Retained earnings | ||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||
| Treasury stock (at cost), 1,158,772 and 871,489 shares at 2026 and 2025, respectively | ||||||||||||||
| Total Core Laboratories Inc. shareholders' equity | ||||||||||||||
| Non-controlling interest | ||||||||||||||
| TOTAL EQUITY | ||||||||||||||
| TOTAL LIABILITIES AND EQUITY |
Loading...